{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:08:56Z","timestamp":1776280136042,"version":"3.50.1"},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,27]]},"DOI":"10.18632\/oncotarget.19856","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T20:35:27Z","timestamp":1501792527000},"page":"90308-90314","source":"Crossref","is-referenced-by-count":6,"title":["Systematic review and meta-analysis comparing zoledronic acid administered at 12-week and 4-week intervals in patients with bone metastasis"],"prefix":"10.18632","volume":"8","author":[{"given":"Ling","family":"Cao","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Dong","family":"Diao","sequence":"additional","affiliation":[{"name":"Department of Oncology, China-Japan Friendship Hospital Affiliated Jilin University, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu-He","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ling","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Wen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, The First Hospital of Jilin University, Changchun, Jilin, 130021, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun 130012, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2","doi-asserted-by":"publisher","first-page":"18670","DOI":"10.1038\/srep18670","article-title":"Natural History of Non-Small-Cell Lung Cancer with Bone Metastases","volume":"5","author":"Ottaviani","year":"2015","journal-title":"Sci Rep"},{"key":"3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ncponc1323","article-title":"Effect of bisphosphonates on pain and quality of life in patients with bone metastases","volume":"6","author":"Major","year":"2009","journal-title":"Nat Clin Pract Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q","article-title":"A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease","volume":"91","author":"Von Teichert","year":"2001","journal-title":"Cancer"},{"key":"5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Seaman","year":"2001","journal-title":"Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4103\/0973-1482.126471","article-title":"Zoledronic acid treatment for cancerous bone metastases: a phase IV study in Taiwan","volume":"9","author":"Chao","year":"2013","journal-title":"J Cancer Res Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial","volume":"100","author":"Abella","year":"2015","journal-title":"Haematologica"},{"key":"8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/jjco\/hyi005","article-title":"A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy","volume":"35","author":"Takashima","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/jco.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Von Roenn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S2046","article-title":"Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women","volume":"3","author":"Papadias","year":"2008","journal-title":"Clin Interv Aging"},{"key":"11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial","volume":"317","author":"O'Mara","year":"2017","journal-title":"Jama"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial","author":"Lipton","year":"2017","journal-title":"JAMA Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/s1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Ripamonti","year":"2013","journal-title":"Lancet Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Lazzarino","year":"2007","journal-title":"Leukemia"},{"key":"15","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases","volume":"7","author":"Lipton","year":"2001","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1093\/annonc\/mdv284","article-title":"Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis","volume":"26","author":"Clemons","year":"2015","journal-title":"Ann Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Altman","year":"2010","journal-title":"Int J Surg"},{"key":"18","doi-asserted-by":"publisher","first-page":"65577","DOI":"10.18632\/oncotarget.11576","article-title":"The use of and adherence to CTCAE v3.0 in cancer clinical trial publications","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"19","unstructured":"Higgins. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available from wwwcochrane-handbookorg. 2011."},{"key":"20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jbo.2013.03.001","article-title":"De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists","volume":"2","author":"Clemons","year":"2013","journal-title":"J Bone Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1177\/154405910708601102","article-title":"Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates","volume":"86","author":"Kimmel","year":"2007","journal-title":"J Dent Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Martinez","year":"2012","journal-title":"J Bone Miner Res"},{"key":"23","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00520-011-1230-9","article-title":"Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists","volume":"19","author":"Clemons","year":"2011","journal-title":"Support Care Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/s1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clemons","year":"2004","journal-title":"Lancet Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-014-3015-6","article-title":"Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study","volume":"146","author":"Levine","year":"2014","journal-title":"Breast Cancer Res Treat"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:03:45Z","timestamp":1596733425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":25,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017,10,27]]}},"alternative-id":["19856","29163830"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19856","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}